Palliative treatment for HIV-related Kaposi's sarcoma by Barnardt, P & Georgiev, GD
HIV AND CANCER
P Ilarnardt, ME CkE, Dip On<ol Chzmorhu
G D Georgiev, MD, MMuI (RaJ On<ol)
lJep<rnmnu of1I<ldiatiml 0naJIDgy,1Y~ Ho,piud, 1Yg~,wCope




Our study included 54 males and 46 females with HIV-
related KS, who were seen and treated between April 1995
and November 2002. The mean age for the group as a
whole was 35.8 years (range 21 - 60 years), the mean age
for females being 34.2 years (range 21 - 58 years) and the
mean age for males 37.1 years (range 21 - 60 years). Of the
patients 69 were black, 27 of mixed racial origin and 4
white. The male/female ratio was 1.1:1. Sixty-one patients
(61%) presented with KS as their AIDS-defining illness and
39 developed KS during the course of their HIV disease. Ten
patients (IO%J were homosexual men. Fifty-three patients
(53%) were treated for concomitant pulmonary
tuberculosis (PTB) [fable n.
Optimal or standard therapy for AIDS-related KS has not
been defined. The major goals of treatment are palliation of
symptoms, shrinkage of tumour to alleviate oedema and
psychological stress, and prevention of disease progression.
All patients presented with generalised mucocutaneous KS
lesions and 56 had additional generalised
lymphadenopathy. Fifteen patients had systemic disease
This ongoing study evaluated the effectiveness of palliative
treatment in patients with HIV-related KS in the absence of
ART.
The HIV situation has changed since antiretroviral therapy
(ARn became available: deaths from AIDS-related illnesses
have been reduced by 75%. A projected reduction
in new KS cases of 50 - 90% and regression of existing KS
is now a recognised benefit of ART.' The clinical response
correlates with a decrease in the HIV viral load and an
increase in the CD4+ count'
People with AIDS are at considerably higher risk of
developing cancer than the general population. Frisch et
01.' reported that most of the cancers observed in HIV/AIDS
patients were those already considered to be AIDS-defining
cancers (87%), notably Kaposi's sarcoma (KS) and non-
Hodgkin's lymphoma (NHl).
Objective. To evaluate palliative treatment with
chemotherapy and/or radiotherapy in patients with
HIV-related Kaposi's sarcoma (KSJ. The primary end-
point was symptom relief; the secondary end-point
was tumour response to treatment and overall
survival.
Methods. This study indudes 100 patients with HIV-
related KS. Combination chemotherapy was
administered with ABV (doxorubicin, bleomycin and
vincristine) (33 patients), or vinblastine and bleomycin
(Vbl-B) (48 patients), depending on the CD4+ count at
presentation. Radiotherapy was administered to 31
patients.
Results. Symptomatic relief was noted within 4 weeks
of chemotherapy and response after 8 weeks. Twenty-
nine patients (29'lbJ had partial responses, 8 patients
(8'!bJ achieved complete responses, and 37 patients
(37llbJ had stable disease. Twenty-six patients (26llb)
had disease progression. The response rate was 37%,
with dinical benefit achieved in 74% of patients.
Patients who received radiation therapy for bleeding
and painful ulcers had complete responses. Twenty-
seven patients (27%) received 8 Gray (GyJ single
fractions. Two lower-half bodies (8 GyJ and one upper-
half body (6 GyJ were irradiated. Five patients received
a course of radiation for nasopharyngeal and skeletal
lesions (20 Gy), rectal lesions (30 Gy) and an eyelid
lesion (12 Gy). Forty-two patients (42%) are alive, with
a median survival of 11.2 months (range 2 - 49
months). Fifty-eight patients (58llb) died due to
progression of HIV disease or associated opportunistic
infections with a median overall survival of8.8 months
(range 1 - 31 monthsJ.
Conclusion. In the absence of antiretroviral therapy
the care and prognosis of HIV-related Kaposi's
sarcoma remains dismal. However, symptomatic relief
and an improved quality of life can still be offered.
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Fig. 1.1<5: X-ray image ofskeletal involvement.
Fig. 2. 1<5: Clscan image ofrecral mass.
Radiotherapy was offered to patients with CD4+ counts
< 50 cellsl~l, performance status 2 - 3, bleeding, painful
ulcerative lesions, and generalised, painful limb oedema.
ThirtY-one parienrs received concomitant radiation therapy
the CD4+ count was between 30 and 100 cells/~1. ABV was
administered 10 33 pa ients, as first-line therapy in 23
cases and as second-line treatment for fulminating and
progressive disease in 10. Forty-eight patients received the
Vbl-B combination. A cycle of treatment consisted of day 1
and day 15 every 4 weeks. A median of 5 cycles was
administered (range 1 - 15 cycles). A total of 206 cycles of
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TABLE I. PATIENT CHARACTERISTICS
that involved the liver (1 case), spleen (1). lung (9), rectum
(2), pericardial effusion (1) and skeletal involvement (1)
[Rgs 1 and 2)
Because of the multicentric nature of KS, the standard
rumour-node-metastases (TNM) staging system used for
solid rumours cannot be applied to KS. Patients were
assigned to receive treatment according 10 he AIDS
Clinical Trial Group [AClG) staging system developed by the
Na ional Insrirute of Allergy and In'ectious Diseases.
Pa ients were classified in good or poor risk groups based
on tumour extent immune sratus measured by the CD4+
count (>1< 200 cells/~ll. and evidence of HIV-associated
systemic symplOms:' In this patient population there were
26 patients (26010) with good risk sratus while 74 (74010)
presented with advanced poor risk KS. All patients with a
CD4+ count < 200 cells/~1 received sulphamethoxazole +
trimethoprim [Bactrim) as part of Pneumocystis carinii
prophylaxis.
Patients received chemotherapy with either the
combination ABV (doxorubicin 10 mglm', bleomycin
10 mglm' and vincristine 2 rng) every 2 weeks if rhe CD4+
coum was> 100 cells/~l, or the combinarion vinblastine





KS is the most common malignancy associated with HIV.
The single most important risk factor for the development
of AIDS-related KS is immune suppression." The
recognition that effective antiretroviral regimens are
associated with both a decrease in new AIDS-defining KS
cases and a regression in the size of existing KS esions
resulted in the recommendation mat' I -positive patien s
be treated wi:h antireuoviral orugs. ART prolo gs the time
lO treatment 'a'lure 0' anti-KS rherapies. In paf(icular, since
the use of pro ease inhibitors a 30 - 50~o reduction of KS
has oeen observeo in rhe USA ana Europe." The resolution
of immune suppress'on witn ART mignt a so aFect KS..··· It
is thought mer prmease inhibitors may inhibir the KS-
associated herpesvirus proreins, but it is more likely that KS
regression is linked to adecrease in rhe HIV replicarion with
an associated decrease of cytokine levels leading to the
restoration of immune funC'Cion:
DISCUSSION
Fig. 3. Overall survival of 100 parienrs I/irh HIV-refared KS
strarified according to good ana poor risk groups.
Because of :he unpreaic:ab e responses of KS :0 ART,
spec'rc loca ara/or systemic treraoy 's often :rs:ilU!ed.
Forry-two (42%) of this patient population are currently
alive, with a median survival of 11.2 months (range 1 - 49
months). Fifty-eight patients (58%) died due to progression
of their HIV disease or associated opportunistic infections
- pneumonia (10 cases), Cryptococcus neoformons
meningitis (2), Mycobacterium tuberculosis (6), sys emic
candidiasis (3) and fever of unknown origin I2l. with a
median overall survival of 8.8 montns (range 1 - 31
months) (Fig. 3).
Twenty-nine patients (29%) had partial responses, while 26
(26%) experienced disease progression. Eight pa ients (80/0)
achieved comple:e responses and 37 [37%) ad stable
disease, with an overall response or 740'0.
In this stuoy 61~o of patients presented with KS as their
AIDS-defining illness. Thirty-nine pa ients developed KS as
parr of the natural course of HIV, a mean of 31.6 months
after diagnosis (range 6 - 120 months).
RESULTS
All 100 patients are evaluable for response and 58 patients
for overall survival. All patients receiving treatment had
symptomatic relief within the first two administrations (4
weeks) and responses within the first twO cycies (8 weeks)
0' chemotherapy. Patients generally tolerated
chemomerapy well. aema otoxicity requiring treatment
delays were ooserved in 6 patients w:th graae 3
ne tropenia. All 27 patients receiving 8 Gy 'ractiors
responoeo 'or the indications of pain and bleeding ulcers.
Five pOlients receiving a pro racteo course of irradiation all
had complete responses. Three patients receiving naif-body
radiation had partial symptomatic relief. Two patients who
received radiation therapy for bleeding oropharyngeal
lesions experienced prolonged radiarion-induced mucositis,
grade 3 [World Health Organsation). The duration of
response for campi ere resoonaers was 9.1 months (2.5 - 30
montns), woile :he d rae'on 0' symp:orrar'c re 'ef was 4.1
,"on:'s (1 - 8 mon:rs).
The CD4+ count was done at the start of treatment and
repeated after every second cycle of cytotoxic treatmenL
The mean CD4+ count was 172.8 cells/~1 [range 0 - 750
cells/~1) at onser, and a depletion of 18.8% of the CD4+
count was observed by the end of treatment, with a mean
of 140.3 cells/~1 (range 0 - 769 cellsl I). The study
suggested that women present at a younger age (mean
34.2 years, range 21 - 58 years) and with more advanced
disease (mean CD4+ count 125 cells/~l, range 0 - 409
cells/~l) than males, for whom the median age at
presentation was 37.1 years (range 21 - 60 years) and the
mean CD4+ count 214 cells/~1 (range 2 - 750 cells/~I).
while 9 had radiation therapy as their only form of
treatment. Single 8-Gray (Gy) fractions were given in 27
patients and were repeated in 9 patients on day 28. Two
lower-half bodies [8 Gy) and one upper-half body (6 Gy)
were irradiated. A protracted course of irradiation with
cobalt-60 was administered to 5 patients: 1with bleeding
rectal KS received 30 Gy (3 Gy x 10 fractions); 2 with
bleeding nasopharyngeal KS received 20 Gy (4 Gy x 5
fractions); 1 with humerus involvement received 20 Gy (4
Gy x 5 fractions); and 1 with eyelid involvement received
consolidation radiation with 12 Gy (3 Gy x 4 fractions)
electrons, after a pa rtia I response to 4 cycles of ABV.
The ACTG Oncology Committee evaluates tumour
responses on the basis of total-body cu aneous lesion
co ntS, changes in lesio character (fiat or raised) and
bidimensional measurements of marker lesio s. Partial
responses (PR) are based on a 500,'0 reduction in the total
number of lesions or a 500/0 decrease in the n mber of
raised lesions. Response is never based on improvement of
symptoms or visceral disease alone.';
Optimal ART with maximal viral suppression, prevention
and treatment of opportunistic infections is an essential
element of KS treatment
Many chemotherapeutic agents are active against KS, both
as single agents and in combination. In most series, the
overall response rates range from 25% to 76%, although
most have been partial responses."" In our series, an
overall clinical benefit rate of 74% was observed with
chemotherapeutic agents, even though the current
systemic treatment for KS revolves around liposomal
anthracyclines and paclitaxel.
Neither ART nor liposomal
anthracyclines are standard
treatment in the public
health sector. The absence of
ART is reflected in the overall
survival of AIDS-related KS
patients, with a median
overall survival of 8.8 months
(range 1 - 31 months).
The absence of improved
survival rates for AIDS-
related KS patients is
generally attributed to the
decline in CD4+ count.
Chemotherapy can deplete
CD4+ counts by up to 50%
independent of HIV and thus
limit the CD4+ protective
effect of ART." This study
showed a decline of 18.8% in
the CD4+ count from a mean
of 1728 cells/~l to a mean of 140.3 cells/~1.
In spite of significantly improved overall survival rates for
patients with AIDS, the survival of patients with KS has
remained poor. A European AIDS cohort study reported a
median survival of 17 months for patients with KS."
Fernandez Guerrero et 0/.' reported that the median
survival of patients with KS on ART was 49 months in
comparison with 12 months for patients who did not
receive ART. In our study 42% of patients are alive with a
median survival of 11.2 months (range 2 - 49 months). Four
patients with amedian survival of 29.5 months are on ART.
Fifty-eight patients (58%) died due to progression of their
HIV and HIV-related illnesses, with a median overall
survival of 8.8 months (range 1 - 31 months). Thirty-nine
per cent of deaths were due to opportunistic infections:
pneumonia, Cneoformons meningitis, systemic candidiasis
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and M. tuberculosis. Twelve patients died of progressive KS.
The high proportion of patients (61%) presenting with KS
as their AIDS-defining illness reflects the ignorance and
stigma about HIV/AIDS that still persist in communities.
This emphasises the need for continuous education and
information as a priority of HIV/AIDS prevention. Despite
the high frequency of KS, the referral system seems
inadequate as a limited number of patients are referred for
treatment Factors that could account for this include




Survival rates are still failing
to improve among our
patients owing to advanced
disease, accompanied by
opportunistic infections, and
the absence of ART. However,
symptomatic relief and an
improved quality of life can
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